Warning: The NCBI web site requires JavaScript to function. more...
Can discrete event simulation be of use in modelling major depression?
Le Lay A, Despiegel N, François C, Duru G.
Cost Eff Resour Alloc. 2006 Dec 5;4:19.
Related citations
A review and critique of modelling in prioritising and designing screening programmes.
Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J, Madan J.
Health Technol Assess. 2007 Dec;11(52):iii-iv, ix-xi, 1-145. Review.
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.
Comparison of Markov model and discrete-event simulation techniques for HIV.
Simpson KN, Strassburger A, Jones WJ, Dietz B, Rajagopalan R.
Pharmacoeconomics. 2009;27(2):159-65. doi: 10.2165/00019053-200927020-00006.
Modelling the treated course of schizophrenia: development of a discrete event simulation model.
Heeg B, Buskens E, Knapp M, van Aalst G, Dries PJ, de Haan L, van Hout BA.
Pharmacoeconomics. 2005;23 Suppl 1:17-33.
Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R, Pitt M, Somerville M, Stein K, Price A, Gilbert N.
Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. Review.
Final Report on Carcinogens Background Document for Styrene.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.
Final Report on Carcinogens Background Document for Formaldehyde.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A, O'Hagan A, Moore D.
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. Review.
The measurement and monitoring of surgical adverse events.
Bruce J, Russell EM, Mollison J, Krukowski ZH.
Health Technol Assess. 2001;5(22):1-194. Review.
Prevention of suicide and attempted suicide in Denmark. Epidemiological studies of suicide and intervention studies in selected risk groups.
Nordentoft M.
Dan Med Bull. 2007 Nov;54(4):306-69. Review.
Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.
Karnon J.
Health Econ. 2003 Oct;12(10):837-48.
Recent developments in decision-analytic modelling for economic evaluation.
Weinstein MC.
Pharmacoeconomics. 2006;24(11):1043-53. Review.
Emerging methods in economic modeling of imaging costs and outcomes a short report on discrete event simulation.
Hollingworth W, Spackman DE.
Acad Radiol. 2007 Apr;14(4):406-10. Review.
Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications.
Guo S, Bozkaya D, Ward A, O'Brien JA, Ishak K, Bennett R, Al-Sabbagh A, Meletiche DM.
Pharmacoeconomics. 2009;27(1):39-53. doi: 10.2165/00019053-200927010-00005.
A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.
Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.
Sources, pathways, and relative risks of contaminants in surface water and groundwater: a perspective prepared for the Walkerton inquiry.
Ritter L, Solomon K, Sibley P, Hall K, Keen P, Mattu G, Linton B.
J Toxicol Environ Health A. 2002 Jan 11;65(1):1-142. Review.
Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis.
Tappenden P, Chilcott JB, Eggington S, Oakley J, McCabe C.
Health Technol Assess. 2004 Jun;8(27):iii, 1-78. Review.
Depression and Chronic Obstructive Pulmonary Disease: Treatment Trials.
Borson S, Claypoole K, McDonald GJ.
Semin Clin Neuropsychiatry. 1998 Apr;3(2):115-130.
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.
Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on